Literature DB >> 17452146

Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting.

E Marc Jolicoeur1, Christopher B Granger, John L Fakunding, Steven C Mockrin, Steven M Grant, Stephen G Ellis, Richard D Weisel, Margaret A Goodell.   

Abstract

This article reviews the progress in cell therapy for cardiovascular disease and examines the opportunities to accelerate the process to clinical application. It draws from a meeting of the National Heart, Lung, and Blood Institute Working Group on Translation of Cell-based Therapies for Cardiovascular Disease in August 2004 to assess the status of clinical studies of cell-based therapies for cardiovascular disease, to determine the gaps in knowledge and barriers that prevent the implementation of well-designed and safe clinical studies, and to identify the areas of opportunity to apply cell-based therapies for cardiovascular disease to facilitate the clinical implementation of cell-based therapies for cardiovascular disease. We present the perspectives of experts in stem cell biology, cardiovascular physiology, cardiology, clinical research, and regulatory issues confronting the field of cell therapy for cardiovascular disease.

Entities:  

Mesh:

Year:  2007        PMID: 17452146     DOI: 10.1016/j.ahj.2007.02.028

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Cellular therapies for heart disease: unveiling the ethical and public policy challenges.

Authors:  Amish N Raval; Timothy J Kamp; Linda F Hogle
Journal:  J Mol Cell Cardiol       Date:  2007-11-22       Impact factor: 5.000

2.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.

Authors:  Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop
Journal:  Cell Stem Cell       Date:  2009-07-02       Impact factor: 24.633

3.  Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells.

Authors:  Junji Moriya; Napoleone Ferrara
Journal:  Cardiovasc Diabetol       Date:  2015-02-07       Impact factor: 9.951

4.  Is stem cell-based therapy going on or out for cardiac disease?

Authors:  Ki Hyun Byun; Sung-Whan Kim
Journal:  Korean Circ J       Date:  2009-03-25       Impact factor: 3.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.